Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

5(38%)

Results Posted

140%(7 trials)

Phase Distribution

Ph phase_4

Ph phase_1

15%

Ph phase_3

46%

Ph phase_2

23%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution12 total trials

Phase 1Safety & dosage

2(16.7%)

Phase 2Efficacy & side effects

3(25.0%)

Phase 3Large-scale testing

6(50.0%)

Phase 4Post-market surveillance

1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Completed(5)

Detailed Status

Completed5

Active, not recruiting3

Not yet recruiting3

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (16.7%)

Phase 23 (25.0%)

Phase 36 (50.0%)

Phase 41 (8.3%)

Trials by Status

active_not_recruiting323%

completed538%

not_yet_recruiting323%

recruiting215%

Recent Activity

5 active trials

Showing 5 of 13

not_yet_recruitingphase_3

Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

NCT07571161

recruitingphase_3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789

completedphase_2

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

NCT03367403

active_not_recruitingphase_3

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

NCT05026866

not_yet_recruitingphase_4

Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

NCT06911944

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT07571161Phase 3

Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

Not Yet Recruiting

NCT05508789Phase 3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Recruiting

NCT03367403Phase 2

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

Completed

NCT05026866Phase 3

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active Not Recruiting

NCT06911944Phase 4

Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

Not Yet Recruiting

NCT05738486Phase 3

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

Active Not Recruiting

NCT06566170

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Recruiting

NCT04437511Phase 3

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Active Not Recruiting

NCT06996730Phase 2

A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

Not Yet Recruiting

NCT04640077Phase 2

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

Completed

NCT05108922Phase 3

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Completed

NCT05567159Phase 1

A Study of Donanemab (LY3002813) in Healthy Participants

Completed

NCT05533411Phase 1

A Study of Donanemab (LY3002813) in Healthy Chinese Participants